Development of pharmaceuticals is a costly and risky affair, and therefore, rightfully, merits great reward. “Generic” alternatives are affordable, but it takes away the incentive from drug companies which make the investments, do the testing, and risk lawsuits only to see their profits dwindle when other companies “copy” their findings and offer the same drug cheaper.
Snyder believes that if the government insists that prescription drugs be made more affordable to poorer citizens, the government should compensate drug companies with tax cuts or other benefits.
|
